Cytokinetics (CYTK)
CYTK - NASDAQ - 3/12/2010 8:00 PM
| Market Cap | Revenue Growth | Profit Margin | Cash |
|---|---|---|---|
| $204.86M | 76.04% | -148.82% | $121.58M |
| 2921 / 4569 | 183 / 4568 | 4352 / 4566 | 1560 / 4096 |
For the September 2009 quarter, Cytokinetics spent 179.09% of gross profits on R&D and 70% on SGA expenses. Revenues rose 76.04% year-over-year to $5.51M. The company is trading at 8.22 times earnings(PE) and 2.45 times revenue(PSR). At the end of September 2009, Cytokinetics had $121.58M in cash on hand and $1.33M in long-term debt. On 10/28/2009, Cytokinetics reported net loss of $8.20M, with diluted earnings per share of $-0.14.
